Steven Cohen's ANAB Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 55,303 shares of AnaptysBio, Inc. (ANAB) worth $3.07 M, representing 0.00% of the portfolio. First purchased in 2019-Q1, this long-term strategic position has been held for 26 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in ANAB, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 2.37 M shares. Largest reduction occurred in Q1 2026, reducing 1.88 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's AnaptysBio (ANAB) Holding Value Over Time
Track share changes against reported price movement
Quarterly AnaptysBio (ANAB) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -1.88 M | Reduce 97.14% | 55,303 | $55.46 |
| Q4 2025 | -332,638 | Reduce 14.68% | 1.93 M | $48.48 |
| Q3 2025 | -209,346 | Reduce 8.46% | 2.27 M | $30.62 |
| Q2 2025 | +106,504 | Add 4.50% | 2.47 M | $22.20 |
| Q1 2025 | +2.37 M | New Buy | 2.37 M | $18.59 |
| Q4 2024 | -54,200 | Sold Out | 0 | $0.00 |
| Q3 2024 | +36,300 | Add 202.79% | 54,200 | $33.50 |
| Q2 2024 | -846,200 | Reduce 97.93% | 17,900 | $25.06 |
| Q1 2024 | +75,555 | Add 9.58% | 864,100 | $22.52 |
| Q4 2023 | -2,655 | Reduce 0.34% | 788,545 | $21.42 |
| Q3 2023 | -668,709 | Reduce 45.80% | 791,200 | $17.96 |
| Q2 2023 | -221,238 | Reduce 13.16% | 1.46 M | $20.34 |
| Q1 2023 | -443,053 | Reduce 20.86% | 1.68 M | $21.76 |
| Q4 2022 | -402,000 | Reduce 15.91% | 2.12 M | $30.99 |
| Q3 2022 | +1.67 M | Add 196.57% | 2.53 M | $25.51 |
| Q2 2022 | -465,800 | Reduce 35.35% | 851,800 | $20.30 |
| Q1 2022 | +1.06 M | Add 412.40% | 1.32 M | $24.74 |
| Q4 2021 | +257,145 | New Buy | 257,145 | $34.75 |
| Q1 2021 | -760,300 | Sold Out | 0 | $0.00 |
| Q4 2020 | +760,300 | New Buy | 760,300 | $21.50 |
| Q3 2020 | -210,886 | Sold Out | 0 | $0.00 |
| Q2 2020 | +210,886 | New Buy | 210,886 | $22.34 |
| Q1 2020 | -25,900 | Sold Out | 0 | $0.00 |
| Q4 2019 | +25,900 | New Buy | 25,900 | $16.25 |
| Q2 2019 | -33,600 | Sold Out | 0 | $0.00 |
| Q1 2019 | +33,600 | New Buy | 33,600 | $73.04 |
Steven Cohen's AnaptysBio Investment FAQs
Steven Cohen first purchased AnaptysBio, Inc. (ANAB) in Q1 2019, acquiring 33,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held AnaptysBio, Inc. (ANAB) for 26 quarters since Q1 2019.
Steven Cohen's largest addition to AnaptysBio, Inc. (ANAB) was in Q1 2025, adding 2,368,370 shares worth $44.03 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 55,303 shares of AnaptysBio, Inc. (ANAB), valued at approximately $3.07 M.
As of the Q1 2026 filing, AnaptysBio, Inc. (ANAB) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in AnaptysBio, Inc. (ANAB) was 2,526,200 shares, as reported at the end of Q3 2022.